Announcements

    Drinks

      THURSDAY, 25/01/2018 - Scope Ratings AG
      Download PDF

      Sanofi ratings unaffected by Bioverativ acquisition

      Scope believes that the recently announced USD 11.6 bn acquisition of US-based biotech company Bioverativ is not a challenge for Sanofi’s credit rating.

      While the transaction, which is still pending regulatory approval, is fully funded by a combination of cash and additional debt, its likely negative impact on Sanofi’s financial risk profile is of insignificant relevance in the context of the ratings. This is not to say credit metrics will not deteriorate in 2018 compared to the previous year, but Scope believes that the likely deterioration will not be strong enough to justify a negative rating action.

      Scope had stated in its last outlook statement that the rating reflects Sanofi being able to maintain the following Scope-adjusted credit metrics: funds from operations to debt of 60%, and free operating cash flow to debt of at least 40%. The agency does not believe that the acquisition of Bioverativ is likely to endanger these thresholds meaningfully and can thus maintain the ratings.

      Related news

      Show all
      Scope upgrades MET HSP’s issuer rating to BB- from B+ and revises Outlook to Stable from Positive

      20/5/2025 Rating announcement

      Scope upgrades MET HSP’s issuer rating to BB- from B+ and ...

      Scope downgrades issuer rating of Wellis to CCC, places it under review for a possible downgrade

      15/5/2025 Rating announcement

      Scope downgrades issuer rating of Wellis to CCC, places it ...

      Scope affirms A+/Stable issuer rating of Austrian utility EVN AG

      14/5/2025 Rating announcement

      Scope affirms A+/Stable issuer rating of Austrian utility EVN AG

      Webinar: where is the global economy headed amid global tariff uncertainty?

      7/5/2025 Research

      Webinar: where is the global economy headed amid global ...

      Scope publishes analytical report on Lyse

      6/5/2025 Monitoring note

      Scope publishes analytical report on Lyse

      Scope affirms AXIÁL’s BB issuer rating, revising the Outlook to Stable from Negative

      6/5/2025 Rating announcement

      Scope affirms AXIÁL’s BB issuer rating, revising the Outlook ...